Brain cancer is one of the most aggressive forms of cancer. Patients typically survive less than a year.

But more than a year after undergoing an experimental treatment for glioblastoma, Australian doctor Richard Scolyer remains cancer-free, defying the grim prognosis associated with this aggressive brain cancer.

Prof. Scolyer, a world-renowned pathologist and joint 2024 Australian of the Year, became the first patient to receive pre-surgery combination immunotherapy—an approach inspired by his own groundbreaking melanoma research.

The treatment, which also included a personalized cancer vaccine, aims to harness the body’s immune system to attack the tumor. While the odds of a cure remain uncertain, his latest MRI scan showed no recurrence, sparking excitement about potential advancements in brain cancer treatment.

Although Prof. Scolyer faced significant challenges during treatment, including seizures and pneumonia, he now feels healthier than he has in years and continues his daily fitness routine. His remarkable progress offers hope for the 300,000 people diagnosed with brain cancer annually.

While researchers stress that much work remains before this approach becomes a standard treatment, the promising results have led to ongoing studies that could transform glioblastoma care. Prof. Scolyer, supported by his colleague Prof. Georgina Long and an expert medical team, remains optimistic that his case will pave the way for future clinical trials and new treatment possibilities.